1 and CD4 1 T cell subsets, and natural killer and natural killer T cells. Here, we describe a hitherto unreported role of IL-15 in regulating homoeostasis of naive CD4 1 T cells. Adoptive transfer of splenocytes from non-obese diabetic (NOD) mice results in increased homeostatic expansion of T cells in lymphopenic NOD.scid.Il15 2/2 mice when compared to NOD.scid recipients. The increased accumulation of CD4 1 T cells is also observed in NOD.Il15 2/2 mice, indicating that IL-15-dependent regulation also occurs in the absence of lymphopenia. NOD.scid mice lacking the IL-15Ra chain, but not those lacking the common gamma chain, also show increased accumulation of CD4 1 T cells. These findings indicate that the IL-15-mediated regulation occurs directly on CD4
INTRODUCTION IL-15 is a member of the gamma chain (c c , CD132) family of cytokines. 1 The IL-15 receptor (IL-15R) complex also shares the IL-2 receptor (IL-2R) beta chain (IL-2/15Rb, CD122). The unique alpha chain (IL-15Ra, CD215) of the trimeric IL-15R complex binds IL-15 during biosynthesis and trans-presents IL-15 to the IL-15Rbc c complex on the same cell or on adjacent responder cells. 2 Trans-presentation of IL-15 is required for the maintenance of several lymphoid cell subsets such as natural killer, natural killer T and memory CD8 1 T cells. 3, 4 While IL-7 is essential for the survival of naive T lymphocyte subsets, 5 IL-15 promotes the survival of memory CD8
1 T cells. 6 However, IL-15 signaling can occur during all stages of CD8 1 T cell development. [7] [8] [9] In line with these observations, a recent report suggests that trans-presentation of IL-15 is required to support the expansion of CD8 1 single positive thymocytes. 9 IL-15 also appears to sustain CD8
1 effector T cells generated following weak T-cell receptor (TCR) stimulation by low-affinity antigens. 10, 11 Whereas the effect of IL-15 on CD8 1 T cells has been well documented, its influence on CD4 1 T cells is less clear. IL-15 is reported to be required for the maintenance of 'memory-like' and antigen-specific memory CD4
1 T cells, but it is unclear if IL-15 is also required for their activity. 12, 13 In vitro, IL-15 has been shown increase CD4
1 T-cell proliferation by suppressing regulatory CD4
1 T cells. 14, 15 Contrarily, other reports have shown that IL-15 supports the expansion of CD4 1 CD25 1 regulatory T cells. [16] [17] [18] While it is possible that IL-15 may influence both regulatory and target CD4
1 T-cell populations in vitro, the scenario may be different in vivo, where additional inflammatory mediators may modulate the effect of IL-15. For instance, even though the frequency of circulating regulatory T cells (Tregs) is increased in patients with rheumatoid arthritis, they are not capable of regulating the pathogenic process, in which IL-15 plays a key role. play a key pathogenic role, but CD4
1 T cells are also needed for disease initiation. Recently, we have reported that IL-15 deficiency in NOD mice prevented the development of T1D. 21 We have also shown that adoptive transfer of splenocytes from diabetic NOD mice induced T1D in NOD.scid recipients, but not in NOD.scid.Il15 2/2 recipients. 21 In this adoptive transfer setting, CD8
1 T-cell numbers gradually diminished in NOD.scid.Il15 2/2 recipients. Curiously, we consistently recovered higher numbers of CD4 1 T cells from these mice. In the present study, we characterized the CD4 1 T cells that are undergoing expansion in IL- 15- /SzJ) were obtained from the Jackson Laboratory (Bar Harbor, ME, USA). Generation of NOD.scid.Il15 2/2 mice has been described previously.
21
C57BL/6.Il15ra 2/2 mice were obtained from the Jackson Laboratory and backcrossed to NOD background for nine generations before crossing them with NOD.scid mice to generate NOD.scid.Il15ra 2/2 mice. The characteristics of IL-15-related strains used in this study are given in Table 1 .
Antibodies and reagents
Antibodies against mouse CD3e, CD4, CD8a, CD44, CD62L, CD25, CD69 and IFN-c, conjugated to flurochromesor biotin and streptavidin-flurochromes conjugates were purchased from BD Pharmingen Biosciences (Palo Alto, CA, USA) or eBiosciences (San Diego, CA, USA). RPMI 1640 cell culture medium and fetal bovine serum were from Sigma-Aldrich (Oakville, Canada). 5-(6)carboxyfluoresceindiacetatesuccinimidyl ester (CFSE) was purchased from Molecular Probes, Life Technologies Inc. (Burlington, Ont., Canada). MHC class III-A(g7)-restricted peptide derived from the mouse chromogranin A protein (ChgA [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] ; DTKVMKCVLEVISD) 22 and MHC class-I H2K b -restricted cognate peptide of 8.3 TCR derived from the islet-specific autoantigen glucose-6-phosphatase catalytic subunit-related protein ; VYLKTNKFL) 23 were synthesized by GenScript (Scotch Plains, NJ, USA) to .95% purity.
Mononuclear cell preparation, adoptive transfer and in vivo proliferation assay Mononuclear cell suspensions were prepared from individual lymph nodes or spleen as described previously.
11 CD4 1 T cells were purified by negative selection using kits from Dynal Beads (Life Technologies Inc., Ont., Canada). In vivo cell proliferation was evaluated using CFSE-dye dilution assayas described before. 11 Two million CFSE-labeled or unlabeled splenocytes from the indicated donors were injected intravenously into NOD.scid, NOD.scid.Il15 2/2 , NOD.scid.Il15ra 2/2 or NOD. scid.gamma recipients. Mononuclear cell suspensions prepared from individual lymph nodes, or spleen were analyzed for sequential reduction in dye content within CD4 1 T cells. 1 T cells isolated from pre-diabetic donor NOD or 8.3-NOD mice, respectively, and labeled with CFSE were used as responder cells at a ratio of 1 effector cell to 1 putative regulatory cell (each at a concentration of 1310 6 cells/ ml) along with 0.2310 6 irradiated NOD splenocytes as antigen-presenting cells in 500 ml medium in 24-well plates. To evaluate anti-TCR (2C11)-induced proliferation, the responder and putative regulatory cells were plated together. To evaluate inhibition of antigen-induced proliferation of 8.3 cells, the putative regulatory CD4
1 cells were pre-stimulated with anti-CD3 antibody for 24 h and washed to remove excess antibody before adding to responder cells and antigenpresenting cells. After 3 days, proliferation of responder cells was evaluated by monitoring dilution of CFSE fluorescence on gated CD4
1 or CD8 1 T cells.
Western blotting
Purified 2310 6 CD8 1 or CD4 1 T cells were washed and resuspended in starving medium (medium containing 0.5% fetal bovine serum, 1 mg/ml bovine serum albumin and 50 mM 
Yes No
Common gamma chain-deficient NOD.scid.gamma
Yes Yes
Abbreviations: NOD, non-obese diabetic; TCR, T-cell receptor; Tg, transgenic.
2-mercaptoethanol) before stimulation with IL-15 (10 ng/ml) in a volume of 0.5 ml. Fifteen minutes after stimulation, cells were lysed by boiling in SDS-PAGE sample buffer (50 mM Tris pH 6.8, 1% (w/v) SDS, 1 mM EDTA, 1 mM dithiothreitol). Equivalent amounts of proteins were separated in SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. The blots were probed with phospho-specific antibodies and developed by enhanced chemiluminescence reagent (GE-Amersham, GE Healthcare, Canada). After incubating in stripping solution (2% SDS, 62.5 mM Tris pH 6.8, 100 mM 2-mercaptoethanol) for 30 min at 55 uC, the blots were blocked and reprobed for total proteins.
Flow cytometry
Expression of cell surface markers was evaluated by flow cytometry using FACS Canto flow cytometer (Becton Dickinson flow cytometry systems, Missisauga, Canada) and the data were analyzed using the FlowJo software (Tree Star Inc., Ashland, OR, USA).
Adoptive transfer and diabetes monitoring
Splenocytes from 6 months old non-diabetic NOD.Il15
NOD mice were injected intravenously (3310 7 cells) into 1-month-old female NOD recipients. Control mice received PBS. Diabetes was monitored using urine glucose strips (Ketodiastix; Bayer, Canada). Animals with two consecutive readings of .3 (corresponding to 15 mmol/l glucose) were considered diabetic.
Statistical analyses
Cumulative incidence of T1D was analyzed using the Prism software (GraphPad, La Jolla, CA, USA) and statistical significance was calculated using log-rank (Mantel-Cox) test. For all other parameters, significance was calculated by two-way ANOVA.
RESULTS

Trans-presented IL-15 regulates homeostatic expansion of CD4
1 T cells Phenotypic analysis of cells recovered from the NOD.scid and NOD.scid.Il15 2/2 recipients 2 months after adoptive transfer of splenocytes from NOD mice showed a reduction in the frequency of CD8 1 T cells in the lymph nodes ofNOD. scid.Il15 2/2 hosts 21 ( Figure 1a ). However, we consistently recovered more CD4 1 T cells from NOD.Scid.Il15 2/2 recipients than from NOD.scid or NOD.scid.gamma recipients (Figure 1b ). These observations prompted us to investigate whether donor CD4
1 T cells could use IL-15 available in recipient mice, although IL-15 deficiency was not reported to affect the CD4 1 T-cell compartment in NOD or C57BL/6 mice. 21, 24 To this end, we purified CD4 1 T cells, exposed them to IL-15 and evaluated downstream STAT signaling. As shown in Figure 1c (Figure 2a) . However, this expansion was more pronounced in NOD.scid.Il15 2/2 mice than in NOD.scid or NOD.scid.gamma recipients. These observations indicated that IL-15 attenuated homeostatic expansion of CD4 1 T cells. Next, we assessed if IL-15 needs to be trans-presented to exert this regulation, we used NOD.scid mice lacking IL-15Ra as recipients. As shown in Figure 2b , NOD.scid.Il15ra 2/2 mice also showed increased expansion of CD4 1 T cells, indicating that trans-presentation of IL-15 by non-T cells is needed to control homeostatic expansion of CD4 1 T cells.
Regulation of homeostatic expansion of CD4 1 T cells by IL-15 occurs in a cell autonomous manner and is influenced by basal TCR signaling To rule out the possibility that the increased expansion of CD4 1 T cells could be a compensatory effect due to the reduced expansion of CD8
1 T cells, we evaluated homeostatic expansion of purified CD4
1 T cells in NOD.scid and NOD.
scid.Il15 2/2 recipients. We also used splenocytes from MHC II-restricted BDC2.5 TCR Tg mice. 25 The BDC2.5 TCR Tg CD4
1 T cells recognize a peptide derived from the islet specific antigen chromogranin A. 22 Both polyclonal and monoclonal donor CD4
1 T-cell populations showed accelerated expansion in NOD.scid.Il15 2/2 mice compared to NOD.scid recipients (Figure 3a and b) , indicating that the increased expansion of CD4 1 T cells does not result from the lack of competition from CD8 1 T cells. This increased expansion was not restricted to pancreatic draining lymph nodes, but occurred in all lymph nodes with similar efficiency (Figure 3b ). This observation suggested that TCR avidity towards self-peptides might influence the IL-15-dependent control of CD4 1 T-cell expansion during lymphopenia. We have previously shown that NOD and NOD.Il15 2/2 mice bearing polyclonal TCR harbor comparable numbers of CD4 1 T cells in spleen and lymph nodes. 21 Therefore, we tested whether IL-15 deficiency would deregulate homeostasis of BDC2.5 cells under non-lymphopenic conditions. We used BDC2.5 cells because of their higher propensity to undergo homeostatic expansion in NOD.scid.Il15 2/2 hosts (Figure 3a and b) . Surprisingly, BDC2.5 cells underwent robust proliferation in NOD.Il15 2/2 recipients when compared to wild-type NOD mice (Figure 3c ). This finding indicates that IL-15 dependent regulation of CD4 1 T-cell homeostasis can occur even under non-lymphopenic conditions. (Figure 4a and b) . Despite the presence of activated CD8 1 and CD4 1 T cells, splenocytes recovered from NOD.scid.Il15 2/2 recipients failed to induce diabetes upon subsequent transfer to IL-15-sufficient NOD.scid recipients. 21 The loss of pathogenic potential of these cells that had survived in an IL-15-deficient environment for a brief period may result from at least two mutually non-exclusive possibilities: (i) IL-15 is required to maintain the effector T cells that cause diabetes; and (ii) absence of IL-15 might have expanded a subset of regulatory CD4
1 T cells (Tregs) that inhibited the pathogenic potential of diabetogenic T cells. To assess whether the increased homeostatic expansion of CD4
1 T cells in NOD.scid.Il15 2/2 mice resulted in the expansion of Tregs, we evaluated the expression of FOXP3 in CD25
1
CD4
1 T cells recovered from NOD.scid.Il15 2/2 and NOD.scid recipients. In both groups of mice, the proportion of FOXP3
1
CD25
1 CD4 1 T cells was negligible ( Figure 5a ). Next we tested whether CD4 2/2 mice did not prevent the development of T1D in NOD mice ( Figure 6 ). In fact, the NOD.Il15 2/2 splenocyte-reconstituted mice and the control mice developed T1D with similar kinetics, indicating that the CD4 1 T cells expanding in the absence of IL-15 do not acquire the capacity to regulate T-cell responses in vivo.
CD4
1 cells undergoing homeostatic expansion in the absence of IL-15 show reduced antigen responsiveness and effector cytokine production In NOD.scid.Il15 2/2 recipients, the absolute number of 8.3 TCR Tg CD8 1 T cells that had undergone homeostatic expansion was decreased, even though they still retained their ability to proliferate in the presence of cognate antigen. 21 To determine if this was also the case in CD4
1 T cells, we assessed the antigen reactivity of BDC2.5 cells that had expanded in NOD.scid.Il15 2/2 mice. As shown in Figure 7a , the phenotype of CD4
1 T cells recovered from IL-15-or IL-15Ra-deficient mice 10 days after adoptive transfer was comparable to that recovered from the control NOD.scid mice. However, following stimulation with the cognate peptide, BDC2.5 cells recovered from NOD.scid mice showed efficient upregulation of markers of activation such as CD25 and CD69, whereas cells recovered from NOD.scid.Il15 2/2 or NOD.scid.Il15ra 2/2 mice were not activated efficiently (Figure 7b, left panels) . In 3 (a, b) or at the indicated days (c) after adoptive transfer were analyzed. Representative data from at least two independent experiments (5-6 mice per group) are shown. CFSE, 5-(6)carboxyfluorescein diacetate succinimidyl ester; NOD, nonobese diabetic.
IL-15 regulates homeostasis of CD4
1 T cells XL Chen et al addition, the production of IFN-c was reduced in cells recovered from IL-15-or IL-15Ra-deficient mice (Figure 7b , right panels). These results suggest that IL-15 and its trans-presentation promote the antigen responsiveness of CD4 1 T cells.
DISCUSSION
Homeostatic expansion of specific subsets of T cells is driven by cytokines such as IL-7 and IL-15, as well as basal TCR signaling through engagement of MHC-self-peptide complexes. 26 Naive T cells require IL-7 and TCR-MHC interaction, whereas signals through IL-7R and IL-15R are sufficient for the expansion of memory T cells. In a lymphopenic environment, CD8
1 T cells reach normalization by homeostatic expansion, while CD4 1 T cells are chronically depleted. 27,28 IL-7 has been reported to negatively regulate the expansion of CD4 1 T cells by modulating the expression of MHC class II molecules on dendritic cells. 29, 30 In the present study, we show that IL-15, which promotes homeostasis and survival of CD8
1 T cells, may simultaneously control the expansion of CD4 1 T cells. In fact, IL-15 may exert differential effect on different subsets of CD4 1 T cells as it has been shown to promote the expansion of memory CD4
1 T cells in mice and in humans. 13, 26, 31 Our results obtained using T cells from young donor mice suggest that IL-15 inhibits the homeostatic expansion of naïve CD4 1 T cells. Moreover, the use of genetically immunodeficient NOD.scid recipients instead of irradiated hosts avoids competition from endogenous thymus-derived T cells. Given that thymus continually exports naive T cells and the size of the T cell pool is limited, we propose that IL-15-mediated regulation of peripheral CD4
1 T-cell expansion may facilitate the expansion and survival of memory T-cell subsets. We also speculate that the restriction on the expansion of naive T cells in the periphery may serve as a safety mechanism to contain the expansion of potentially autoreactive CD4
1 T cells that are otherwise kept under check by peripheral tolerance mechanisms under steady state. Overall, our findings raise the possibility that cytokines such as IL-7 and IL-15 that promote homeostatic expansion of certain T-cell subsets may also negatively regulate the expansion of certain other T-cell subsets.
The observed increase in the homeostatic expansion of CD4
1 T cells is cell intrinsic and is a direct consequence of the absence of trans-presentation of IL-15 by the nonlymphoid cells of the host for the following reasons. The increased expansion is observed in both lymphopenic and non-lymphopenic IL-15-deficient hosts, irrespective of whether the injected cells were purified CD4
1 T cells or total splenocytes (Figures 2 and 3) . The requirement for trans-presentation of IL-15 by non-T cells is evident from increased expansion in NOD.scid.Il15ra
2/2
hosts but not in NOD.scid.gamma recipients (Figure 2b ). This requirement for trans-presentation also suggests that the physiological amount of soluble IL-15 that is available in circulation may not be able to bind to IL-15Ra that is expressed on donor CD4
1 T cells. Thus, CD4 1 T cells are also dependent on trans-presented IL-15 in vivo, similar to CD8 1 T cells. 3 Moreover, the IL-15-mediated suppression of CD4 1 T-cell expansion is regulated directly by signals through the IL-15 receptor complex on T cells rather than indirectly through its effect on other cell types because this increased expansion does not occur in NOD.scid.gamma mice lacking the common gamma chain required for IL-15 signaling. It is also possible that the regulation is mediated through cell-cell interaction, of which one component is trans-presented IL-15, as naive CD4 cells do not proliferate in the presence of IL-15. 32 Conflicting reports exist on the role of IL-15 in the generation of T cells with regulatory functions. 17, 18, 33 Van Belle et al. 15 has shown recently that in the presence of IL-15, the suppressive effects of Tregs was diminished in vitro. On the other hand, IL-15 has been shown to promote the development of CD4 1 CD25 1 FOXP3 1 Tregs in humans, 18 consistent with the fact that signaling via CD122 is required for the development of Tregs in vivo. 34 However, the pro-inflammatory effect of IL-15 may play a dominant role on effector T cells in vivo, either directly and/or indirectly via non-lymphoid cells, such that the Tregs are ineffective in suppressing the pathogenicity of effector T cells. 19, 35 Our results ( Figure 5 ) confirm the observation that the absence of IL-15 does not alter the frequency of Tregs. 36 On the other hand, BDC2. suggests that increase in the frequency of autoantigen specific T cells, as observed with TCR Tg mice, may overcome the critical threshold of islet-antigen specific T cells required to cause pathology. 25 Additionally, lack of IL-15 may promote other pathogenic mechanisms. For instance, it has been shown that lack of IL-15 skewed the antigen specific CD4
1 T cells to produce IL-10 or IL-17.
36,37 Accordingly, autoimmune diseases mediated by Th17 cells such as experimental autoimmune encephalomyelitis are aggravated by the absence of IL-15. 36, 37 In this study, we have identified a novel role for IL-15 in restraining the homeostatic expansion of CD4 1 T cells. Thus, IL-7 and IL-15, the two major cytokines that regulate the survival and homeostasis of different subsets of T cells also restrain the expansion of CD4 2/2 mice were injected into 6-week-old female pre-diabetic NOD mice. Splenocytes from six non-diabetic NOD.Il15 2/2 mice were pooled and injected into eight female NOD mice. Control group received PBS. The mice were followed for the development of diabetes by monitoring urine glucose levels. NOD, non-obese diabetic; PBS, phosphate-buffered solution.
IL-15 regulates homeostasis of CD4compartment. It is equally important to study this regulation during immunotherapies using IL-15 to boost the effectiveness of CD8 1 T cells, for instance against cancer. IL-15 regulates homeostasis of CD4
